Clinical classification of pulmonary hypertension.

By G. Simonneau, N. Galiè, Lewis J. Rubin, D. Langleben, W. Seeger, G. Domenighetti, S. Gibbs, D. Lebrec, R. Speich, M. Beghetti and 2 more. Journal of the American College of Cardiology, 2004

1,758 citations recorded by the source corpus.

In 1998, during the Second World Symposium on Pulmonary Hypertension (PH) held in Evian, France, a clinical classification of PH was proposed. The aim of the Evian classification was to individualize different categories sharing similarities in pathophysiological mechanisms, clinical presentation, and therapeutic options. The Evian classification is now well accepted and widely used in clinical practice, especially in specialized centers. In addition, this classification has been used by the U.S. Food and Drug Administration and the European Agency for Drug Evaluation for the labeling of newly approved medications in PH. In 2003, during the Third World Symposium on Pulmonary Arterial Hypertension held in Venice, Italy, it was decided to maintain the general architecture and philosophy of the Evian classification. However, some modifications have been proposed, mainly to abandon the term "primary pulmonary hypertension" and to replace it with "idiopathic pulmonary hypertension"; to reclassify pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis; to update risk factors and associated conditions for pulmonary arterial hypertension and to propose guidelines in order to improve the classification of congenital systemic-to-pulmonary shunts.

Subfields: Cardiology and Cardiovascular Medicine, Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/1376a43877485b5bcd586b5648d6e9fa2b2e3d65

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Virend K. Somers
2. S. Daniels

In Pulmonary and Respiratory Medicine

1. T. Young
2. G. Simonneau

Citations in the corpus

• Pulmonary arterial hypertension in France: results from a national registry. (2006, background): “Our goal was to assess a homogeneous population; therefore, patients with known severe pulmonary function abnormalities (defined as pulmonary function test results for FVC, total lung capacity, or FEV1 60%) were excluded because they are prone to develop another type of pulmonary hypertension second”
• Inflammation, growth factors, and pulmonary vascular remodeling. (2009, background): “erta, Canada; ‡‡Pulmonary Vascular Diseases Unit, Department of Medicine, Univero elated to human immunodeficiency virus (HIV) infecion, drugs, and toxins (1).”
• Pulmonary arterial hypertension (2013, background): “Aminorex, fenfluramine derivatives and toxic rapeseed oil represent the only identified “definite” risk factors for PAH [5,16].”
• Ventilation–Perfusion Scintigraphy Is More Sensitive than Multidetector CTPA in Detecting Chronic Thromboembolic Pulmonary Disease as a Treatable Cause of Pulmonary Hypertension (2007, methodology): “When we analyzed the data considering just the highprobability scans as suggestive of chronic pulmonary thromboembolic disease (V/Q (2)), the sensitivity was 96.”